Angiotensin-II Receptor Antibodies Blockade With Losartan in Patients With Lupus Nephritis

• Status: Unknown status
• Trial end date: 2019-10-31
• Target enrollment: 0
• Participant gender: All

Summary

Antibodies directed against angiotensin-II receptor (AT1-Ab) are agonist antibodies previously studied in human diseases such as preeclampsia, transplantation and scleroderma. They act by binding to the AT1 receptor and their effects can be blocked with the use of angiotensin receptor blockers (ARB). In this randomized open clinical trial the investigators will study the effect of the blockade of AT1-Ab with losartan in carotid intima-media thickness progression in patients with lupus nephritis compared to patients treated with enalapril.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran
• Collaborator: National Council of Science and Technology, Mexico
• Treatments: Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Angiotensinogen; Antibodies; Enalapril; Enalaprilat; Enzyme Inhibitors; Immunoglobulins; Losartan

Criteria

Inclusion Criteria:

• Signed consent form for the study

• Biopsy-proven lupus nephritis with proteinuria > 1.5g/g by 24 hour urine protein to creatinine ratio

• Need for immunosuppressive induction to remission therapy according to the treatment physician

• Systemic lupus erythematosus diagnosis based on at least 4 American College of Rheumatology criteria

• Age between 16 and 50 years

Exclusion Criteria:

• Patient does not want to participate in the study

• Comorbid disease such as diabetes mellitus with macro/microangiopathy, previous diagnosis of hypertension >5 years, scleroderma

• Comorbid findings in the histopathological analysis of the renal biopsy